Loading viewer...
report
Format: PDF report
ZUMA-24 is a Phase 2 study evaluating the safety and efficacy of Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma in outpatient settings.
brochure
report
Chevron
report
FTS International
report
BNY
report
Banner Corporation